EVO logo

EVOTEC SE - SPON ADR

EVONASDAQ
🏆 #2905 by market capEarnings Nov 5US Equity
$911.86▼ $68.57 (−7.52%)
Simulated price
🔔
Track EVO
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 7.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$559M
Small Cap
📈Revenue Growth (YoY)
-5.0%
Declining
📊Gross Margin
10.5%
Thin
💵FCF Margin
-22.6%
Thin
⚖️P/S Ratio
0.7x
Cheap
Otter Score
60
Fair
No chart data available for EVO.

Trading Snapshot

Day Range
$906.85 – $918.30
52-Week Range
$1.50 – $4.27
Volume
$4.39B
Avg Volume
$4.78B
Shares Outstanding
355.2M
Next Earnings
Oct 28, 2026

Fundamentals Snapshot

Annual Revenue
$757M
Last Q Revenue
$146M
P/E Ratio
-2.6
P/S Ratio
0.7x
EPS (TTM)
$-0.55
Dividend Yield
0.00%
Dilution (1yr)
+0.2%

Why Investors Own EVO

  • ✓High-growth profile — revenue up +43.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 44% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EVO logo

EVOTEC SE - SPON ADR

EVO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$757M▼ −5.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
8.3%▼ −42.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$135M▼ −5.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$79M▼ −30.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
355.5M▲ +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$29M▲ +$108M YoY
StockOtter · stockotter.space

About EVOTEC SE - SPON ADR

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$1,033.43
▲ +13.3% Upside
High Target$1,267.96
Low Target$966.32
Based on 27 analysts

Latest News & Updates

🚀
Barron’s·2h ago

EVOTEC SE - SPON ADR tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift EVO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

EVOTEC SE - SPON ADR announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.